medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (2)


Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial

Stine JG, Wang J, Cornella SL, Behm BW, Henry Z, Shah NL, Caldwell SH, Northup PG

Idioma: Ingles.
Referencias bibliográficas: 19
Paginas: 300-306
Archivo PDF: 147.00 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, Navasa M, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993: 105: 229-36.

  2. Gines P, Schrier RW. Renal failure in cirrhosis. N Eng J Med 2009:361:1279-1290. doi: 10.1056/NEJMra0809139; 10.1056/NEJMra0809139.

  3. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. New Engl J Med 1998:339:533-541. doi: 10.1056/NEJM199808203390807.

  4. Moreau R, Durand F, Poynard T, et al. Duhamel C, Cervoni JP, Ichaï P, Abergel A, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002: 122: 923-30.

  5. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007: 56: 1310-18. doi: 10.1136/gut.2006.107789.

  6. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8. doi: 10.1053/j.gastro.2008.02.014; 10.1053/ j.gastro.2008.02.014.

  7. Singh V1, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, Sharma AK, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012; 56: 1293-8. doi: 10.1016/j.jhep.2012.01.012; 10.1016/j.jhep.2012.01.012.

  8. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology (Baltimore, Md.) 1989; 9: 349-51.

  9. Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J Hepatol 2006; 45: 280-9. doi: 10.1016/j.jhep.2006.02.013.

  10. Tahir F, Riaz H, Rehman A, Munir MB. Potential role of TNF alpha blockers in delaying the progression of hepato-renal syndrome. Medical Hypotheses 2012; 78: 225-6. doi: 10.1016/j.mehy.2011.10.030; 10.1016/j.mehy.2011.10.030.

  11. Fernández-Rodríguez CM, Lledó JL, López-Serrano P, Gutiérrez MA, Marcos Alonso S, Pérez-Fernández MT, Férnández Gil MA, et al. Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis--a randomized double-blind placebo- controlled trial. Revista Española de Enfermedades Digestivas: Órgano Oficial de la Sociedad Española de Patología Digestiva 2008; 100: 481-9.

  12. Tyagi P, Sharma P, Sharma BC, Puri AS, Kumar A, Sarin SK. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: a pilot randomized control trial between pentoxifylline and placebo. Eur J Gastroenterol Hepatol 2011; 23: 210-17. doi: 10.1097/MEG.0b013e3283435d76; 10.1097/MEG.0b013e3283435d76.

  13. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-48.

  14. Lebrec D, Thabut D, Oberti F, et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010; 138: 1755-62. doi: 10.1053/j.gastro.2010.01.040; 10.1053/ j.gastro.2010.01.040.

  15. Runyon BA, Aasld. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology (Baltimore, Md.) 2013; 57: 1651-3. doi: 10.1002/hep.26359; 10.1002/hep.26359.

  16. Ortega R, Calahorra B, Gines P. Vasoconstrictors in the treatment of hepatorenal syndrome. Nefrología: 2002; 22 (Suppl.)5: 56-61.

  17. Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, Bataller R, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.

  18. Colle I, Durand F, Pessione F, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002; 17: 882-8.

  19. Kamath PS1, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70. doi: 10.1053/jhep.2001.22172.




2020     |     www.medigraphic.com